Jump to content

WHO issues warning on weight loss drug Wegovy


New weight loss drugs such as Wegovy will not be a “silver bullet” in tackling obesity, the World Health Organization (WHO) has warned.

Francesco Branca, WHO director of food and nutrition safety, said weight loss drugs must be used alongside a healthy diet and exercise.

Ms Branca’s comments come as the health body conducts its first review of obesity management guidelines in two decades.

Semaglutide, marketed as Wegovy by drugmaker Novo Nordisk, is an appetite suppressant drug that has been approved by the UK medicines regulator and described by some as a “game changer” in helping people to shed weight.

People will only be given Wegovy on prescription as part of a specialist weight management service involving input from several professionals and for a maximum of two years.

Some experts described the decision as a “pivotal moment” for the treatment of people living with obesity but others warned that the drug is not a “quick fix”.

Read full story

Source: The Independent, 12 May 2023

0 Comments


Recommended Comments

There are no comments to display.


Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...